Patient, Provider & Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of Higher-Risk MDS

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of disorders of the blood-forming stem cells in the bone marrow and results in lower than normal numbers of one or more types of blood cells. A rapidly evolving treatment landscape and changes to prognostic scoring systems have created a practice gap for healthcare providers treating patients with MDS.

This multimedia-based activity is designed for health care professionals to explore the diagnosis and treatment of MDS through a unique perspective that puts the patient voice front and center. In addition to renowned expert, Naval Daver MD, who will discuss implementation of current and emerging treatment options in the management of MDS; Christian Laubscher MHS PA-C, a physician assistant at the University of Texas MD Anderson Cancer Center will share her perspective on best practices for facilitating shared decision-making with her patients. The activity will also include a patient with higher risk MDS who will lend expertise by sharing her personal journey of living with MDS. The activity focuses on steps along the continuum of care: screening, diagnosis, and referral to initiation of treatment, treatment during disease progression, management of adverse events, and shared decision-making that occurs along the way.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

This educational activity is directed toward physicians, NP/PAs, nurses, and other members of the healthcare team involved in the treatment of patients with HR-MDS.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain evidence-based recommendations for MDS diagnosis and risk stratification
• Demonstrate the impact of risk assessment on decision-making among patients with higher-risk MDS along the disease continuum
• Evaluate the efficacy and safety profiles for current and emerging treatment approaches in patients with higher-risk MDS
• Translate recent clinical evidence from landmark trials into personalized treatment plans for patients with higher-risk MDS, with a focus on patient education and shared decision-making

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Chair

Naval G. Daver, MD
Associate Professor
Director of the Leukemia Research Alliance Program
Department of Leukemia
MD Anderson Cancer Center (MDACC)
Houston, TX

Disclosures: Research Funding: AbbVie, Amgen, Astellas, Bristol-Meyers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, Novimmune, Pfizer, Sevier, Trillium, Trovagene; Advisory/Consulting: Daichii-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Arog, Novartis, Jazz, Celgene, Syndax, Shattuck, Labs, Agios.

Faculty

Christian A. Laubscher, MHS, PA-C
Advanced Practice Provider
Department of Leukemia
MD Anderson Cancer Center (MDACC)
Houston, TX

Disclosures: Christian A. Laubscher, MHS, PA-C has no relevant financial relationships with ineligible companies.

Judy DiBattiste
Patient

Disclosures: Judy DiBattiste has no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.